Form 4: Zimmer Biomet Director Kurdikar Reports Phantom Stock Unit Acquisition

Director Devdatt Kurdikar reports acquisition of phantom stock units in Zimmer Biomet Holdings, Inc. under the Deferred Compensation Plan for Non-Employee Directors.

Summary

• Devdatt Kurdikar, a director of Zimmer Biomet Holdings, Inc., reported the acquisition of phantom stock units on December 31, 2024.
• The transaction involved the accrual of 130.048 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The price of the phantom stock units was $105.73.
• These units are to be settled in shares of company common stock within sixty days after cessation of the reporting person's service as a Director.
• Following the reported transaction, Kurdikar beneficially owns 384.961 phantom stock units.
• This amount includes 0.564 phantom stock units accrued October 31, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding director compensation, indicating a neutral sentiment.

Future Outlook

The phantom stock units will be settled in shares of Zimmer Biomet common stock within sixty days after cessation of the reporting person's service as a Director.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies. It reflects part of the overall compensation strategy for board members.

Stakeholder Impact

• Shareholders may be interested in director compensation practices.
• The filing provides transparency regarding director holdings in the company.

Key Dates